쇼트리드 시퀀싱 시장

Global Short-Read Sequencing Market to Reach US$24.7 Billion by 2032

The global market for Short-Read Sequencing estimated at US$11.8 Billion in the year 2025, is expected to reach US$24.7 Billion by 2032, growing at a CAGR of 11.2% over the analysis period 2025-2032. Next-Generation Sequencing, one of the segments analyzed in the report, is expected to record a 10.8% CAGR and reach US$16.4 Billion by the end of the analysis period. Growth in the Sanger Sequencing segment is estimated at 11.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.4 Billion While China is Forecast to Grow at 10.4% CAGR

The Short-Read Sequencing market in the U.S. is estimated at US$3.4 Billion in the year 2025. China, the world's second largest economy, is forecast to reach a projected market size of US$4.3 Billion by the year 2032 trailing a CAGR of 10.4% over the analysis period 2025-2032. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 9.9% and 9.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 9.0% CAGR.

Global Short-Read Sequencing Market - Key Trends and Drivers Summarized

How Is Short-Read Sequencing Transforming Genomics?

Short-read sequencing is a next-generation sequencing (NGS) technology that reads short fragments of DNA, typically between 100 and 300 base pairs. It is widely used in genomics for applications such as whole-genome sequencing, targeted sequencing, and RNA sequencing. Renowned for its high accuracy, scalability, and cost-effectiveness, short-read sequencing plays a critical role in research areas like cancer genomics, personalized medicine, and microbiome studies. As advancements in bioinformatics enhance data analysis capabilities, short-read sequencing continues to be a powerful tool for understanding genetic variation, disease mechanisms, and population genetics.

What Are the Key Segments in the Short-Read Sequencing Market?

Key technologies include Illumina sequencing and Ion Torrent sequencing, with Illumina sequencing holding a major share due to its high accuracy, extensive throughput, and broad application range. Applications span across oncology, infectious disease research, genetic testing, and agricultural genomics, with oncology accounting for a significant market share as cancer research and diagnostics rely heavily on DNA sequencing for precision medicine. End-users include research institutions, clinical laboratories, pharmaceutical companies, and academic centers, with research institutions leading the market due to their focus on genomics studies and disease research.

How Is Short-Read Sequencing Being Used Across Research and Clinical Applications?

In oncology, short-read sequencing is used for detecting somatic mutations, copy number variations, and gene fusions, facilitating personalized cancer treatment strategies. Infectious disease research leverages short-read sequencing to identify pathogens, track outbreaks, and study antimicrobial resistance, supporting public health initiatives. Genetic testing applications utilize short-read sequencing to identify genetic disorders, aiding in diagnostics and reproductive health management. In agriculture, short-read sequencing is applied in crop genomics and breeding programs to improve yield, resistance, and nutritional value. Additionally, the integration of bioinformatics and cloud computing has enhanced the analysis of large-scale sequencing data, enabling more accurate and faster genomic insights.

What Factors Are Driving the Growth in the Short-Read Sequencing Market?

The growth in the Short-Read Sequencing market is driven by several factors, including the increasing demand for genomic research in fields like oncology, infectious diseases, and personalized medicine. The growing focus on precision medicine, which relies heavily on genetic insights for tailored treatment, has accelerated the adoption of short-read sequencing in clinical settings. Advancements in sequencing technology, such as higher throughput and reduced costs, have made sequencing more accessible to a broader range of applications. The expanding use of bioinformatics tools and cloud-based data analysis has improved the efficiency of sequencing workflows, supporting broader adoption. Additionally, government funding for genomics research and the development of new diagnostic solutions have contributed to the growth of the short-read sequencing market.

SCOPE OF STUDY:

The report analyzes the Short-Read Sequencing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Technology (Next-Generation Sequencing, Sanger Sequencing); Product (Consumables, Instruments, Services); End-Use (Academic Research, Clinical Research, Hospitals & Clinics, Pharma & Biotech Entities, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

SELECT PLAYERS -

• BGI Genomics Co Ltd.
• CD Genomics
• Element Biosciences
• Illumina, Inc.
• Integra Biosciences AG
• MedGenome, Inc.
• Oxford Nanopore Technologies, Ltd.
• Pacific Biosciences of California, Inc.
• seqWell
• Thermo Fisher Scientific, Inc.

WHAT SETS THIS REPORT APART FROM OTHERS?

Validated Sources - Human-curated validation and ranking of original source content, not AI LLM-generated synthetic content which dominates the internet today and has become a quick fix for most published research reports these days. Unlike most other published sources, our customers have access to full-stack source content. Our report draws from "real intelligence" balancing the power of AI against the risks of synthetically generated content and resulting biases. Customers have access to the source feeds.

Domain Expert Insights - Domain expert insights curated from enterprise, industry, academia, and government, consolidated from multilingual multimedia formats of text, voice, and images comprise a significant resource. Customers can request access to the pool of domain experts we track for this research project. We track 27 domain experts and their insights as part of this research project. Our customers may access our online tracker.

Annual subscription - Recommended for maximum value for your research dollar. Provides one additional full update during the 12 months and access to our research portal and interactive 10-user peer-to-peer collaboration drawing from our entire stack of validated project data which is updated on a weekly basis. Platform also enables adding enterprise data or third-party licensed content to build bespoke versions. Includes competitor tracking of up to 50 companies featured in the report.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
  • How Trump's Tariffs Impact the Market? The Big Question on Everyone's Mind
  • Global Economic Update
  • Short-Read Sequencing - Global Key Competitors Percentage Market Share in 2026 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2026 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Demand for Next-Generation Sequencing (NGS) Spurs Growth in Short-Read Sequencing Market
  • Growing Focus on Genomics, Precision Medicine, and Personalized Therapies Expands Addressable Market
  • Expansion of Short-Read Sequencing in Oncology, Infectious Diseases, and Rare Genetic Disorders Fuels Market Growth
  • Increasing Adoption of Sequencing in DNA Methylation, RNA Sequencing, and Whole Genome Sequencing Expands Market Opportunities
  • Technological Innovations in Library Preparation, Data Analysis, and Bioinformatics Propel Market Expansion
  • Rising Focus on Complying with CLIA, CAP, and ISO Certifications Drives Demand for Short-Read Sequencing
  • Growing Use of Short-Read Sequencing in Drug Discovery, Biomarker Identification, and Microbiome Studies Expands Market Potential
  • Focus on Achieving Rapid Sequencing Turnaround, High Accuracy, and Lower Error Rates Strengthens Market for Short-Read Sequencing
  • Rising Adoption of Sequencing in Agriculture, Synthetic Biology, and Forensics Expands Addressable Market
  • Technological Advancements in Portable Sequencing Devices, Automation, and AI-Assisted Sequencing Propel Market Growth
  • Increasing Focus on Integrating Short-Read Sequencing with Population Genomics and Epidemiology Studies Drives Adoption
  • Rising Demand for Sequencing in Non-Invasive Prenatal Testing (NIPT), Liquid Biopsies, and Cell-Free DNA Analysis Strengthens Global Market
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Recent Past, Current & Future Analysis for Short-Read Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • TABLE 2: World 8-Year Perspective for Short-Read Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2026 & 2032
  • TABLE 3: World Recent Past, Current & Future Analysis for Next-Generation Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • TABLE 4: World 8-Year Perspective for Next-Generation Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2026 & 2032
  • TABLE 5: World Recent Past, Current & Future Analysis for Sanger Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • TABLE 6: World 8-Year Perspective for Sanger Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2026 & 2032
  • TABLE 7: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • TABLE 8: World 8-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2026 & 2032
  • TABLE 9: World Recent Past, Current & Future Analysis for Academic Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • TABLE 10: World 8-Year Perspective for Academic Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2026 & 2032
  • TABLE 11: World Recent Past, Current & Future Analysis for Clinical Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • TABLE 12: World 8-Year Perspective for Clinical Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2026 & 2032
  • TABLE 13: World Recent Past, Current & Future Analysis for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • TABLE 14: World 8-Year Perspective for Hospitals & Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2026 & 2032
  • TABLE 15: World Recent Past, Current & Future Analysis for Pharma & Biotech Entities by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • TABLE 16: World 8-Year Perspective for Pharma & Biotech Entities by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2026 & 2032
  • TABLE 17: World Recent Past, Current & Future Analysis for Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • TABLE 18: World 8-Year Perspective for Consumables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2026 & 2032
  • TABLE 19: World Recent Past, Current & Future Analysis for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • TABLE 20: World 8-Year Perspective for Instruments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2026 & 2032
  • TABLE 21: World Recent Past, Current & Future Analysis for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • TABLE 22: World 8-Year Perspective for Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2026 & 2032
  • TABLE 23: World Short-Read Sequencing Market Analysis of Annual Sales in US$ Million for Years 2020 through 2032

III. MARKET ANALYSIS

• UNITED STATES
  • Short-Read Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2026 (E)
  • TABLE 24: USA Recent Past, Current & Future Analysis for Short-Read Sequencing by Technology - Next-Generation Sequencing and Sanger Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 25: USA 8-Year Perspective for Short-Read Sequencing by Technology - Percentage Breakdown of Value Sales for Next-Generation Sequencing and Sanger Sequencing for the Years 2026 & 2032
  • TABLE 26: USA Recent Past, Current & Future Analysis for Short-Read Sequencing by End-Use - Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 27: USA 8-Year Perspective for Short-Read Sequencing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities for the Years 2026 & 2032
  • TABLE 28: USA Recent Past, Current & Future Analysis for Short-Read Sequencing by Product - Consumables, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 29: USA 8-Year Perspective for Short-Read Sequencing by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Services for the Years 2026 & 2032
• CANADA
  • TABLE 30: Canada Recent Past, Current & Future Analysis for Short-Read Sequencing by Technology - Next-Generation Sequencing and Sanger Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 31: Canada 8-Year Perspective for Short-Read Sequencing by Technology - Percentage Breakdown of Value Sales for Next-Generation Sequencing and Sanger Sequencing for the Years 2026 & 2032
  • TABLE 32: Canada Recent Past, Current & Future Analysis for Short-Read Sequencing by End-Use - Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 33: Canada 8-Year Perspective for Short-Read Sequencing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities for the Years 2026 & 2032
  • TABLE 34: Canada Recent Past, Current & Future Analysis for Short-Read Sequencing by Product - Consumables, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 35: Canada 8-Year Perspective for Short-Read Sequencing by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Services for the Years 2026 & 2032
• JAPAN
  • Short-Read Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2026 (E)
  • TABLE 36: Japan Recent Past, Current & Future Analysis for Short-Read Sequencing by Technology - Next-Generation Sequencing and Sanger Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 37: Japan 8-Year Perspective for Short-Read Sequencing by Technology - Percentage Breakdown of Value Sales for Next-Generation Sequencing and Sanger Sequencing for the Years 2026 & 2032
  • TABLE 38: Japan Recent Past, Current & Future Analysis for Short-Read Sequencing by End-Use - Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 39: Japan 8-Year Perspective for Short-Read Sequencing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities for the Years 2026 & 2032
  • TABLE 40: Japan Recent Past, Current & Future Analysis for Short-Read Sequencing by Product - Consumables, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 41: Japan 8-Year Perspective for Short-Read Sequencing by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Services for the Years 2026 & 2032
• CHINA
  • Short-Read Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2026 (E)
  • TABLE 42: China Recent Past, Current & Future Analysis for Short-Read Sequencing by Technology - Next-Generation Sequencing and Sanger Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 43: China 8-Year Perspective for Short-Read Sequencing by Technology - Percentage Breakdown of Value Sales for Next-Generation Sequencing and Sanger Sequencing for the Years 2026 & 2032
  • TABLE 44: China Recent Past, Current & Future Analysis for Short-Read Sequencing by End-Use - Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 45: China 8-Year Perspective for Short-Read Sequencing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities for the Years 2026 & 2032
  • TABLE 46: China Recent Past, Current & Future Analysis for Short-Read Sequencing by Product - Consumables, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 47: China 8-Year Perspective for Short-Read Sequencing by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Services for the Years 2026 & 2032
• EUROPE
  • Short-Read Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2026 (E)
  • TABLE 48: Europe Recent Past, Current & Future Analysis for Short-Read Sequencing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • TABLE 49: Europe 8-Year Perspective for Short-Read Sequencing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2026 & 2032
  • TABLE 50: Europe Recent Past, Current & Future Analysis for Short-Read Sequencing by Technology - Next-Generation Sequencing and Sanger Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 51: Europe 8-Year Perspective for Short-Read Sequencing by Technology - Percentage Breakdown of Value Sales for Next-Generation Sequencing and Sanger Sequencing for the Years 2026 & 2032
  • TABLE 52: Europe Recent Past, Current & Future Analysis for Short-Read Sequencing by End-Use - Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 53: Europe 8-Year Perspective for Short-Read Sequencing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities for the Years 2026 & 2032
  • TABLE 54: Europe Recent Past, Current & Future Analysis for Short-Read Sequencing by Product - Consumables, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 55: Europe 8-Year Perspective for Short-Read Sequencing by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Services for the Years 2026 & 2032
• FRANCE
  • Short-Read Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2026 (E)
  • TABLE 56: France Recent Past, Current & Future Analysis for Short-Read Sequencing by Technology - Next-Generation Sequencing and Sanger Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 57: France 8-Year Perspective for Short-Read Sequencing by Technology - Percentage Breakdown of Value Sales for Next-Generation Sequencing and Sanger Sequencing for the Years 2026 & 2032
  • TABLE 58: France Recent Past, Current & Future Analysis for Short-Read Sequencing by End-Use - Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 59: France 8-Year Perspective for Short-Read Sequencing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities for the Years 2026 & 2032
  • TABLE 60: France Recent Past, Current & Future Analysis for Short-Read Sequencing by Product - Consumables, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 61: France 8-Year Perspective for Short-Read Sequencing by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Services for the Years 2026 & 2032
• GERMANY
  • Short-Read Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2026 (E)
  • TABLE 62: Germany Recent Past, Current & Future Analysis for Short-Read Sequencing by Technology - Next-Generation Sequencing and Sanger Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 63: Germany 8-Year Perspective for Short-Read Sequencing by Technology - Percentage Breakdown of Value Sales for Next-Generation Sequencing and Sanger Sequencing for the Years 2026 & 2032
  • TABLE 64: Germany Recent Past, Current & Future Analysis for Short-Read Sequencing by End-Use - Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 65: Germany 8-Year Perspective for Short-Read Sequencing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities for the Years 2026 & 2032
  • TABLE 66: Germany Recent Past, Current & Future Analysis for Short-Read Sequencing by Product - Consumables, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 67: Germany 8-Year Perspective for Short-Read Sequencing by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Services for the Years 2026 & 2032
• ITALY
  • TABLE 68: Italy Recent Past, Current & Future Analysis for Short-Read Sequencing by Technology - Next-Generation Sequencing and Sanger Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 69: Italy 8-Year Perspective for Short-Read Sequencing by Technology - Percentage Breakdown of Value Sales for Next-Generation Sequencing and Sanger Sequencing for the Years 2026 & 2032
  • TABLE 70: Italy Recent Past, Current & Future Analysis for Short-Read Sequencing by End-Use - Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 71: Italy 8-Year Perspective for Short-Read Sequencing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities for the Years 2026 & 2032
  • TABLE 72: Italy Recent Past, Current & Future Analysis for Short-Read Sequencing by Product - Consumables, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 73: Italy 8-Year Perspective for Short-Read Sequencing by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Services for the Years 2026 & 2032
• UNITED KINGDOM
  • Short-Read Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2026 (E)
  • TABLE 74: UK Recent Past, Current & Future Analysis for Short-Read Sequencing by Technology - Next-Generation Sequencing and Sanger Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 75: UK 8-Year Perspective for Short-Read Sequencing by Technology - Percentage Breakdown of Value Sales for Next-Generation Sequencing and Sanger Sequencing for the Years 2026 & 2032
  • TABLE 76: UK Recent Past, Current & Future Analysis for Short-Read Sequencing by End-Use - Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 77: UK 8-Year Perspective for Short-Read Sequencing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities for the Years 2026 & 2032
  • TABLE 78: UK Recent Past, Current & Future Analysis for Short-Read Sequencing by Product - Consumables, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 79: UK 8-Year Perspective for Short-Read Sequencing by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Services for the Years 2026 & 2032
• REST OF EUROPE
  • TABLE 80: Rest of Europe Recent Past, Current & Future Analysis for Short-Read Sequencing by Technology - Next-Generation Sequencing and Sanger Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 81: Rest of Europe 8-Year Perspective for Short-Read Sequencing by Technology - Percentage Breakdown of Value Sales for Next-Generation Sequencing and Sanger Sequencing for the Years 2026 & 2032
  • TABLE 82: Rest of Europe Recent Past, Current & Future Analysis for Short-Read Sequencing by End-Use - Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 83: Rest of Europe 8-Year Perspective for Short-Read Sequencing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities for the Years 2026 & 2032
  • TABLE 84: Rest of Europe Recent Past, Current & Future Analysis for Short-Read Sequencing by Product - Consumables, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 85: Rest of Europe 8-Year Perspective for Short-Read Sequencing by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Services for the Years 2026 & 2032
• ASIA-PACIFIC
  • Short-Read Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2026 (E)
  • TABLE 86: Asia-Pacific Recent Past, Current & Future Analysis for Short-Read Sequencing by Technology - Next-Generation Sequencing and Sanger Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 87: Asia-Pacific 8-Year Perspective for Short-Read Sequencing by Technology - Percentage Breakdown of Value Sales for Next-Generation Sequencing and Sanger Sequencing for the Years 2026 & 2032
  • TABLE 88: Asia-Pacific Recent Past, Current & Future Analysis for Short-Read Sequencing by End-Use - Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 89: Asia-Pacific 8-Year Perspective for Short-Read Sequencing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities for the Years 2026 & 2032
  • TABLE 90: Asia-Pacific Recent Past, Current & Future Analysis for Short-Read Sequencing by Product - Consumables, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 91: Asia-Pacific 8-Year Perspective for Short-Read Sequencing by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Services for the Years 2026 & 2032
• REST OF WORLD
  • TABLE 92: Rest of World Recent Past, Current & Future Analysis for Short-Read Sequencing by Technology - Next-Generation Sequencing and Sanger Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 93: Rest of World 8-Year Perspective for Short-Read Sequencing by Technology - Percentage Breakdown of Value Sales for Next-Generation Sequencing and Sanger Sequencing for the Years 2026 & 2032
  • TABLE 94: Rest of World Recent Past, Current & Future Analysis for Short-Read Sequencing by End-Use - Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 95: Rest of World 8-Year Perspective for Short-Read Sequencing by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Academic Research, Clinical Research, Hospitals & Clinics and Pharma & Biotech Entities for the Years 2026 & 2032
  • TABLE 96: Rest of World Recent Past, Current & Future Analysis for Short-Read Sequencing by Product - Consumables, Instruments and Services - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 97: Rest of World 8-Year Perspective for Short-Read Sequencing by Product - Percentage Breakdown of Value Sales for Consumables, Instruments and Services for the Years 2026 & 2032

IV. COMPETITION